DNA甲基化在肺癌顺铂耐药中的研究进展  

Research Progress of DNA Methylation in Cisplatin Resistance in Lung Cancer

作　　者：孙瑾喆 陈骏[1] Jinzhe SUN;Jun CHEN(Department of Oncology,The Second Hospital of Dalian Medical University,Dalian 116000,China)

机构地区：[1]大连医科大学附属第二医院肿瘤科,大连116000

出　　处：《中国肺癌杂志》2023年第1期52-58,共7页Chinese Journal of Lung Cancer

基　　金：辽宁省教育厅科学研究经费项目(No.LJKZ0866)资助。

摘　　要：肺癌作为最常见的恶性肿瘤之一,严重威胁人类的生命健康。铂类药物如顺铂(cisplatin,DDP)是肺癌的一线治疗药物,但其获得性耐药是肺癌治疗的主要难题,也是预后不良的关键原因。顺铂耐药的发生机制较为复杂,确切机制尚未明确。大量研究表明DNA甲基化在肺癌顺铂耐药过程中发挥关键作用,DNA异常高甲基化使染色质构象发生变化,导致多种耐药基因和抑癌基因失活。阐明其复杂机制有望为寻找预测疗效的生物标志物和治疗新靶点的确定提供依据。因此,本文就DNA甲基化在肺癌顺铂耐药过程中的作用和机制做一综述,并总结近年来的去甲基化策略,为逆转肺癌顺铂耐药提供新思路。As one of the most common malignant tumors,lung cancer poses a serious threat to human life and health.The platinum-based drug cisplatin(DDP)is used as the first-line treatment for lung cancer.The poor prognosis of lung cancer is mostly due to developed resistance to cisplatin,which poses a serious treatment challenge.The mechanism of cisplatin resistance is complex and unclear.Numerous studies have shown that DNA methylation plays a crucial role in the emergence of lung cancer cisplatin resistance.DNA hypermethylation results in the deactivation of numerous drug resistance genes and tumor suppressor genes through a change in chromatin conformation.Finding new therapeutic targets and indicators to predict the therapeutic effect can be aided by elucidating the complex mechanism.In order to discover novel strategies to overcome cisplatin resistance in lung cancer,this paper discusses DNA methylation-mediated cisplatin resistance and offers an overview of current demethylation procedures.

关 键 词：肺肿瘤 DNA甲基化 去甲基化 顺铂 耐药性 

分 类 号：R734.2[医药卫生—肿瘤]